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Introduction
The increase in adult type diabetes is becoming a global
epidemic and calls for swift actions to better understand the
disease mechanisms, thus leading to improved targeted
therapies. Emerging knowledge surrounding the role
of microRNAs (miRNAs) in the regulation of post-
transcriptional protein expression has dramatically altered
the view of how target genes are regulated and how they
are involved also in controlling glucose homeostasis. In
addition to an improved understanding of miRNA func-
tions, epigenetic control mechanisms are becoming better
known. Thus, for example the effect of prenatal nutritional
deficiencies and hereditary epigenetic changes, including
DNA methylation and histone modifications are emerging
as important players in the finely tuned balance of fac-
tors ultimately yielding the altered functions under various
pathologic conditions.
Inthisarticle,wereviewthecurrentunderstandingofthe
major epigenetic and post-transcriptional regulatory mech-
anisms with particular emphasis on podocytes during their
injury associated with diabetic kidney damage. It is fore-
seen that this research line will bring major advances in
diagnosticsandunderstandingofpathomechanisms ofboth
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type1and2diabetesandwillleadtoidentificationofnovel
biomarkers and therapeutic targets.
Epigenetic regulation
The term epigenetics is typically defined as heritable
changes in gene expression that are not encoded directly
within the DNA sequence of genes. Epigenetic changes are
crucial for the development and differentiation of the var-
ious cell types in an organism. However, epigenetic states
can become disrupted by environmental influences or dur-
ing ageing, and the importance of epigenetic changes in the
development of cancer and other diseases is increasingly
being discovered.
Eukaryotic genomes are packaged in two general va-
rieties of chromatin: gene-rich euchromatin and geneti-
callyinactiveheterochromatin.Heterochromatinisatightly
packaged form of DNA, and its major characteristic is that
DNA transcription is limited. Centromeres and telomeres
are both heterochromatic (Figure 1). The euchromatin, in
contrast, contains ‘active’ chromatin: DNA sequences that
are being transcribed into RNA [1]. Heterochromatin repli-
cates in the S phase (synthesis phase) of the cell cycle later
than euchromatin, most likely preserving DNA structure
during replication. Heterochromatin also maintains a com-
pact and visible structure during mitosis therefore differing
from euchromatin, which undergoes a typical cycle of con-
densation and unravelling during this process [2].
The DNA packaging densities of these two chromatin
types vary along the length of the chromosome. High-
density heterochromatin regions surround the centromeric
region of the chromosome and have a low amount of
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Fig. 1. Schematic figure of chromatin and histone structure. Chromatin
is the complex of DNA and protein that makes up chromosomes. Het-
erochromatin locates in the centromeric region and telomeres whereas
transcritpionally active euchromatin is located in the less condensed re-
gion. The functions of chromatin are to package DNA into a smaller
volume to fit in the cell, to strengthen the DNA to allow mitosis and meio-
sis and to serve as a mechanism to control expression. The major proteins
involvedinchromatinarehistoneproteins.TheflexibleN-terminaltailsof
thefourcorehistonesH2A,H2B,H3andH4mayundergoarangeofpost-
translationalmodifications,includingacetylation,methylation,O-GlcNac
modification, phosphorylation and ubiquitination, all leading to changes
in the gene expression level.
expressed genes but a high content of repetitive DNA se-
quences including transposons, which are mobile genetic
elements, and highly repetitive DNA regions called satel-
lite DNAs [3]. These two chromatin states are controlled by
reversible epigenetic patterns of DNA methylation and hi-
stone modifications that changes gene expression without
involvingchangesintheDNAsequence(Figure2AandB).
Heterochromatinhasdiverseknownandpostulatedfunc-
tions: maintenance of genome stability, proper chromoso-
mal segregation during mitosis and prevention of telomere
fusion [4]. Heterochromatin also regulates gene expres-
sion by both repression and activation, by directly silenc-
ing genes or by removal of silencing hallmarks of gene
expression [5]. These mechanisms result in considerable
regulatory functions during development and in different
physiologic states of cells.
In addition to the heterochromatin diversity, the mam-
malian genome contains well-defined sequences, which
notably consist of repeats of cytocine-phosphate-guanidine
(CpG) motifs. These areas were earlier considered as non-
functional redundant domains of the chromosomes during
evolution while recent research has revealed strong regu-
latory functions to these elements mainly in influencing
histone modifications and gene-silencing networks within
the cells [6].
In general, the epigenetic regulation of gene
transcription–translation machinery consists of now known
multiple mechanisms for modifying the readout of the ge-
netic code and repression of the chromatin state. In the
context of DNA methylation, sequences within the genome
can be classified into two different groups: CpG-deprived
regions and CpG-rich regions called ‘CpG islands’ (see
Figure 2). CpG islands are defined as being longer than
500 bp and having a GC base content >55% [7]. Consid-
ering their regulatory role, CpG islands are often found in
promoter regions and about half of all genes contain CpG
islands that are situated at the end of the 5  region [8].
Altered methylation status of GC-rich regions may alter
the chromatin structure and typically modulates the finely
tuned promoter-transcription factor interactions with the
transcriptional machinery [9]. This alteration leads to re-
pressed gene expression associated with hypermethylated
CpG islands. In contrast, genomic instability and aberrant
gene expression have been associated with hypomethylated
islands [10]. It has been proposed that more than half of the
repeating 5 -CpG island sequences ultimately participate in
transcription regulation as a result of methylation [11].
Histones are core proteins involved in DNA assembly
and yielding chromatin structure. Histones may dynami-
cally undergo post-translational modifications, which al-
ter their interaction with DNA and nuclear proteins. The
flexible N-terminal tails of the four core histones (H2A,
H2B, H3 and H4, see Figure 1) may undergo a range
of post-translational modifications, including acetylation,
methylation, O-GlcNac modification, phosphorylation and
ubiquitination [12,13] all leading to changes of the genetic
readout. Histone modifications are indicators of active or
repressedchromatin,andthe‘histonecode’hypothesispro-
poses that combinations of specific histone modifications
createacomplexdefiningthefunctionalhierarchyforchro-
matin regulation.
Key enzyme families involved in histone modification
includehistoneacetyltransferases(HATs),histonedeacety-
lases (HDACs), histone methyltransferases and the methyl-
binding domain protein MECP2 [6]. Whereas methylation
of lysine-9 of the histone structure defined as (H3-K9) is a
hallmarkof‘silenced’genomicareathroughoutheterochro-
maticregions,themethylationoflysine4ofhistoneH3(H3-
K4) denotes gain of activity and is found predominantly at
the promoter areas of active genes [14]. The evidence that
several methyl-CpG-binding proteins interact with histone
deacetylase supports a mechanism linking DNA methyla-
tion and histone modifications together (Figure 2C) [15].
In addition, DNA methylation of CpG-rich regions has re-
centlybeenconnectedtohistonedeacetylation,methylation
ofhistoneH3ataspecificsiteoflysine9aswellastodirect
interference by small RNAs [16].
Taken together, remarkable progress has been made in
the understanding of the epigenetic mechanisms by which
the gene readout can be modulated and changes in gene
expression patterns achieved without assuming changes in
the gene coding sequence. While the present understand-
ing may already explain a substantial level of epigenetic
regulation, a comprehensive understanding bringing all the
elements together in understanding distinct pathophysio-
logic entities still remains to be established.
MicroRNA biogenesis
MicroRNAsaresingle-strandedtranscribedRNAsof19–25
nucleotides in length that are generated from endogenous
hairpin structured transcripts throughout the genome [17].
Recent studies have shown that miRNAs have pivotal roles
in diverse gene regulatory pathways, including e.g. control
of timing of developmental processes [18], haematopoietic
cell differentiation [19], apoptosis [20], cell proliferation1090 Nephrol Dial Transplant (2009) 24: Editorial Reviews
Fig. 2. Schematic figure of epigenetic regulation mechanism. DNA methylase catalyze the transfer of a methyl group to the cytosine residues in CpG
dinucleotide sequences (A). Methylation of the CpG islands in the gene promoter region inhibits gene expression (B). Histone acetylation plays an
important role in the regulation of gene expression. Hyperacetylated chromatin is transcriptionally active whereas hypoacetylated chromatin is silent.
Methyl-CpG-binding proteins interact with histone deacetylase causing gene silencing (C).
and organ development [21]. MicroRNAs also represent
one of the largest gene families, accounting for ∼2% of the
whole genome [17]. Efforts to identify the specific miRNA
targets have lead to speculations that miRNAs can directly
regulate the imprint of >90% of human genes [22]. Their
definedfunctionsaskeypost-transcriptionalregulatoryme-
diators are rapidly emerging and have shown to be involved
in the pathogenesis of a variety of diseases [23], including
type 2 diabetes (see Table 1). Even now little is known of
direct miRNA effects in the regulation of the functional
kidney filtration barrier [24].
Biogenesis of miRNAs starts in the nucleus (see
Figure 3) where stretches of several kilobases long primary
miRNAs (pri-miRNAs) are transcribed from the genome,
3 -polyadenylated [covalent linkage poly (A) tail of 3  end
of miRNA], 5 -capped [7-methyl guanylate (m7G) cap of
5  end of miRNA]. Pri-miRNAs are further modified by a
microprocessor that consists of Drosha, a nuclear RNase-
III enzyme, and its essential cofactor called Pasha [25].
This resulting protein complex processes pri-miRNAs into
∼70 nucleotide (nt)-long hairpin-shaped premature miR-
NAs (pre-miRNAs), and the subsequent cleavage at ap-
proximately two helical turns from the loop structure.
Pre-miRNAs bear a two nt 3 -overhang that contributes to
pre-miRNA export out of the nucleus to the cytoplasm by
a RanGTP/exportin-5-dependent mechanism [26]. Dicer, a
cytoplasmicRNaseIIIenzyme,thensubjectspre-miRNAto
a second cleavage step in the cytoplasm. Dicer cleaves near
the hairpin loop to release a short, ∼22 base-pair (bp)-long
incomplete RNA duplex with characteristic two nt-long 3 -
overhangs at both ends that anchor miRNA molecules to
the miRNA-induced silencing complex miRISC [27]. The
miRNA strand having lower thermodynamic stability at
its 5 -end is selectively identified by miRISC and incorpo-
ratedintomiRISCthatcontainsanArgonauteproteinthatis
the catalytic component of RISC, and other protein factors
[28].WhenactivatedbymiRNA,miRISCactsasaneffector
complex of the miRNA pathway interacting with messen-
ger RNA (mRNA). There are several proposed and verified
mechanisms regarding how these genome-originated miR-
NAs can modulate gene and protein expression [29]. It
has been shown that miRNAs exhibiting full complemen-
tarity with target mRNA elicit mRNA degradation via a
mechanism shared with short interfering RNAs (siRNAs).Nephrol Dial Transplant (2009) 24: Editorial Reviews 1091
Table 1. Validated and hypothetic miRNA targets
Validated miRNA targets in type 2 diabetes and in the endocrine system
miRNA Target Function Reference
miR-375 Myotrophin Inhibition of insulin secretion [69]
miR-9 OneCut2 transcription factor Inhibition of glucose-stimulated insulin release [70]
miR-192 E-box repressors TGF-beta-induced matrix protein collagen
Col1a1 and -2
[24]
miR-143 GLUT4, HSL, fatty acid-binding protein aP2,
PPAR-µ2
Adipocyte differentiation [49]
Hypothetic miRNA targets associated with type 2 diabetes
miR-30 family Receptor for advanced glycation end product,
immediate early response 3, vimentin,
heat-shock protein-20
Podocyte apoptosis and cytoskeletal structure [79,80]
miR-23b Hairy/enhancer of the split protein (Hes1) Downstream target of activated Notch signalling
and expressed in nephron segments during
development
[81,84]
miR-15, miR-16 Wnt and β-catenin Nephron induction during embryo development [75,76]
miR-7 GY-box Notch signalling [73,74]
miR-4, miR-79 Brd-box
miR-2, miR-11 K-box
Fig. 3. MicroRNA genesis. Long stretches of immature pri-miRNAs are
transcribedfromthegenome,DroshaanditsmicroprocessorpartnerPasha
processes pri-miRNAs into ∼70 nt long hairpin-shaped pre-miRNAs.
Pre-miRNAs are exported out of the nucleus to the cytoplasm by the
RanGTP/exportin-5-dependent mechanism. Dicer cleaves pre-miRNAs
near the hairpin loop to release a short ∼22 base-pair (bp) long imperfect
RNA duplexes that are further incorporated into the miRISC complex.
MiRNAs exhibiting full complementarity with target messenger RNA
(mRNA) are shown to prompt mRNA degradation. MiRISC may also hin-
der protein translation by several different distinct mechanism including
translational inhibition at the level of initiation and elongation, degrada-
tion of mRNA or the immature protein products or mRNA are segregated
into P bodies for translational inhibition and/or mRNA deadenylation that
causes destabilization of mRNA.
However, in cases of non-perfect complementary bind-
ing to the target mRNA 3 -untranslated region (3 -UTR),
miRISC may hinder protein translation by several different
mechanisms (Figure 3). These mechanisms include trans-
lational inhibition at the level of initiation and elongation,
degradation of mRNA or the immature protein products or
mRNA segregation into P bodies for translational inhibition
and/or by mRNA deadenylation that causes destabilization
of mRNA [30–32]. The outcome of all these mechanisms
either singularly or acting in combination is an effective
regulation of the final mRNA yielding protein expression.
Tools to generate epigenetic and
post-transcriptional profiles
Individual gene expression outcomes in complex diseases,
typically in metabolic disorders such as type 2 diabetes,
are unlikely to completely explain their impact on disease
pathogenesis [33]. Multiple factors are normally needed
to manifest any polygenic human disease. In addition to
DNA mutations and protein post-translational modifica-
tions, well-known factors typically include a complexity
of environmental, dietary and exercise factors while the
epigenetic regulatory mechanisms and any combinations
of the convoluted mechanisms involved appear to be re-
sponsible in an increasing number of disease outcomes
[34]. Present day DNA analytics using robust techniques
of, for example, genome-wide sequencing and mapping
of global single nucleotide polymorphisms (SNPs), may
thus not ultimately yield sufficient knowledge to under-
stand disease pathogenesis. In combination with the new
high-capacity array technologies [35], a new balance be-
tween global genomics, epigenetic gene regulation and
post-transcriptionaleffectsonproteinlandscapeintegrating
thedistinctdatastreamsisneededtobuildacomprehensive1092 Nephrol Dial Transplant (2009) 24: Editorial Reviews
understanding of underlying disease mechanisms in detail
[36].
The huge screening capacity provided by modern
microarrays enable the study of individual factors in-
volved in disease pathogenesis on a genome-wide scale
simultaneously. A wide range of approaches is rapidly
emerging to track the gene targets under epigenetic reg-
ulation and to determine the global changes in genomic
DNA methylation. Customized combinations of these ap-
proaches, based on individual requirements, pave the way
to an in-depth understanding of the processes involved and,
hopefully, will yield better understanding for improved di-
agnostics and for example new targets for better therapies.
Computational public database analysis [available e.g.
at National Center for Biotechnology Information (NCBI,
http://www.ncbi.nlm.nih.gov/), UCSC Genome Bioinfor-
matics group, University of California, Santa Cruz, http://
genome.ucsc.edu/] is a key step in analysing and locating
CpG islands in the promoter region of genes of interest.
Considerable advances have been made in hybridization-
based microarray technologies for genome-wide analysis
for DNA methylation that is designed to discriminate be-
tweenmethylated andunmethylated sequences ingene pro-
moters [36]. A variety of other tools (see Table 2) for
genome-wide discovery of differentially methylated sites
include restriction mapping, bisulfite nucleotide sequenc-
ing, PCR amplification and chromatin immunoprecipita-
tion on DNA microarray (ChIP-on-chip; for an excellent
recent review of the techniques see Ho and Tang [37]).
With current microarray methods, it is also possible to
monitor the effects of DNA demethylating agents (e.g.
5-aza-2 -deoxycytidine) or histone deacetylation inhibitors
(HDACs) by exploring transcription profiles of reactivated
genes [38]. The approaches taken to distinguish miRNA
expression signatures associated with kidney disorders
differ from approaches used to assay DNA methylation
levels because miRNAs interfere at the post-transcriptional
level while DNA methylation influences the transcription
of the genome expression. In addition, it is a challenge
to validate the miRNA target sequences because several
different miRNAs may bind to and cooperatively control
a single mRNA target and, conversely, a single miRNA
can bind to and regulate many different mRNA targets
[39]. Therefore, high-throughput methods supplemented
with extensive in silico data analysis and the subsequent
investigation of the regulation of miRNA-mediated protein
translation typically consist of comparison of protein ex-
pression levels [e.g. difference gel eletrophoresis (DiGE),
mass spectrometry (MS) and western Blot] alongside with
microRNA expression levels (miRNA arrays, qPCR) [40].
Hybridization-based microarrays to detect miRNAs are
based on miRBase Sequence database (http://microrna.
sanger.ac.uk/) that is a searchable database of published
miRNA sequences and their annotations. MiRBase Se-
quence database consists of over 5000 miRNA loci from
58 species, ranging from vertebrates and invertebrates
to prokaryotes including viruses [41]. Recently, next-
generation sequencing (NGS) technology has been shown
to be capable of producing millions of DNA sequence
reads ranging from 35 to 250 base pairs in a single run
(commercially available sequencers: Roche (454) GS
FLX sequencer http://www.454.com/enabling-technology/
the-system.asp; Illumina/Solexa Genome analyser http://
www.illumina.com/; and the Applied Biosystems SOLiD
system http://marketing.appliedbiosystems.com/mk/get/
SOLID_KNOWLEDGE_LANDING). This new technol-
ogy provides multiple advantages when compared to gene
expression microarray platforms, not least in discovering
non-coding RNA sequences, especially novel microRNAs
[42].
The final in vitro miRNA-target validation should be
broughttogetherbyusingpre-miRNAstructuresormiRNA
inhibitors as demonstrated by Tian et al. [42] for example.
O n l yaf e win vitro validated miRNA targets have thus
far been identified using the pre-miRNA hairpin struc-
turesthatmimicnaturalmiRNAmolecules[43].Thesepre-
miRNAs are computationally predicted sequences emerg-
ing from the miRBase Sequence databases and typically
increase the natural miRNA effect. Distinct pre-miRNA
vector constructs as well as synthetic miRNA mimics are
available commercially for miRNA functional analyses and
miRNA-target site validation (e.g. Systems Biosciences,
Mountain View, CA, USA: pre-miRNA clones; Dhar-
macon, Inc. Lafayette, CO, USA: miRIDIAN miRNA
MimicLibrary;Ambion,Inc.AustinTX,USA:Pre-miRTM
miRNA Precursor Molecules) for extensive miRNA target
validation for in vitro and in vivo purposes. Recently, it was
shown that synthetic single stranded mature miRNAs or
hairpin pre-miRNA structures cannot replace endogenous
miRNAs already present in RISC [44]. This affects the
validation of miRNA targets by exogenous miRNA mimic
structures.
Antisense DNA oligonucleotides (ASOs) and anti-
miRNA oligonucleotides (AMOs, antagomirs) are consid-
ered as a practical approach for specific pharmacological
inhibitionofmiRNAfunction[45].Therearetwosuggested
strategies to target miRNA function in vitro and in vivo.
First, ASOs are designed for RNaseH-mediated targeted
degradation of pri-miRNA molecules in nucleus [46]. The
stereochemistry at the 2 -position of the ribose has been
shown to be a major determinant in the target RNA-binding
affinity and the activation of RNaseH [47]. Most common
chemical modifications are phosphorothioate (PS) back-
bone modification combined with 2 -O-methyl (2 -O-Me)
or with 2 -O-methoxyethyl (2 -O-MOE) antisense RNA
oligomersormixedlockednucleicacid(LNA)-DNAASOs
[46].Thebase-pairinteractionbetweenmaturemiRNAand
mRNA is another logical target for an inhibitor. AMOs
are targeting mature miRNA molecules in cytoplasm and
designed to block its function in miRISC [46]. Whereas
pre-miRNA structures and unmodified single stranded
mature miRNA molecules were not able to dissociate en-
dogenous miRNAs from RISC, chemically modified ribo-
oligonucleotides have been shown to present with this po-
tential [44]. AMOs consist of chemical modifications of
2 -ribose and/or phosphate backbone (including 2 -O-Me,
2 Fluoro, 2 -O-MOE, LNAs and PS backbone modifica-
tions) essential in protecting AMOs against endonuclease-
mediated degradation and in improving affinity to target
miRNA molecules [46]. MiRNA–mRNA base-pair inter-
action has successfully been interrupted by transfecting
modified AMOs complementary to miRNAs leading toNephrol Dial Transplant (2009) 24: Editorial Reviews 1093
Table 2. Techniques to analyse DNA methylation
Method Description Reference
Methylation-sensitive restriction mapping
(MSRF)
PCR-based method for genomic DNA after BstU1 (CG specific,
methylation sensitive) and/or MseI (non-CG specific) digestion
[85]
Restriction landmark genomic scanning (RLGS) Genome-wide screening method based on two dimensional
separation of genomic DNA fragments containing radiolabel at
the NotI restriction sites (GC-rich regions)
[86]
Methylated CG island amplification (MCA) Amplification of DNA sequences with closely spaced (<1 kb)
methylated SmaI sites that are commonly found in CG islands
[87]
Differential methylation hybridization (DMH) Array-based method allows genome-wide screening of
differentially methylated CG islands between two samples
[88]
Bisulphite sequencing Sequencing-based method. Bisulfite treatment of genomic DNA
converts cytosine to uracil, but 5-methylcytosine remains
nonreactive
[89]
Methylation-specific oligonucleotide array
(MSO)
Array-based high throughput method. Detection of methylation
status of GC-rich genomic DNA fragments by comparison of
signal intensities between the paired ‘methylated’ and
‘unmethylated’ oligonucleotide probes
[90]
DNA demethylating agents and gene expression
analysis
Detection of reactivated gene expression after treatment of DNA
demethylating agent (e.g. 5-aza-2 deoxycytosine) by gene
expression microarrays
[38]
Genome-wide methylation array/promoter array Human and mouse CpG island/promoter arrays are constructed
based on the CG island library containing CG-rich DNA
fragments. University Health Network Microarray Center
(UHNMC, Toronto, www.microarray.ca)
[91]
Chromatin immunoprecipitation on DNA
microarray (ChIP-chip)
The DNA fragments isolated from chromatin immunoprecipitation
assay are used as targets in a microarray
[92]
Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry
(MALDI-TOF-MS)
Method is based on analysis and precise quantification of
methylation on CpG positions and patterns in genomic DNA by
MALDI-TOF-MS
[93]
blockage of the miRNA–RISC complex [48]. Esau et al.
applied [49] 2 -O-MOE phosphorothioate-modified anti-
senseRNAoligonucleotidestargetingmiRNAsanddemon-
strated the potential inhibition of adipocyte differentiation
by a mir-143 antagomir.
Epigenetic regulation in diabetes
Epigenetic modulating mechanisms have recently been es-
tablished as a massive regulatory machine that cannot be
ignoredinsearchingforanewmechanisticunderstandingof
metabolicsyndrome,obesityandtype2diabetes[50].Type
2diabetesistypicallycharacterizedbyacombinationofpe-
ripheral insulin resistance with an insulin secretion defect
thatvariesinseverity.Theknownmechanismsfordisrupted
insulin secretion in type 2 diabetes include accumulated
damage caused by hyperglycaemia, hyperlipidaemia and
oxidative stress in combination [51,52]. Oxidative stress
and reactive oxygen species have been shown to directly
affect DNA methylation pattern and histone organization,
therefore tuning the expression of multiple genes [53]. In
addition, early nutritional status and possible intrauterine
deprivation of nutrients have been shown to strongly im-
pact the long-lasting DNA methylation effects directed at
the genome readout [54] with immediate effects on devel-
opment. A proposed mechanism includes effects by dietary
methyl and cofactor sources, such as vitamin B12 and folic
acid [55] linked to single-carbon metabolism providing the
methylgroupsforallbiologicalmethylationreactions.Dur-
ing embryonic development, the genome undergoes exten-
sive demethylation followed by remethylation, and appro-
priate DNA methylation status must be maintained over the
roundsofrapidcellularproliferationsteps[56].Unbalanced
methyl donors from nutrition during embryonic develop-
ment may thus irreversibly affect the DNA methylation
patterns [57]. Therefore, extremes of nutritional availabil-
ity and distinct environmental factors have been suggested
toinfluencetheepigeneticmodificationsinhumangenome
and to enhance susceptibility to altered epigenetic pattern
and later to metabolic disorders and adult chronic diseases
[58]. Epidemiological studies have indicated that sub- or
super-optimal nutrient provision in utero may lead to spe-
cific chromatin modifications as described above and have
been proposed as mechanisms associated with the world-
wide epidemic of type 2 diabetes [59]. To support this
hypothesis, dietary protein restriction of pregnant rats typi-
cally associated with hypomethylation of e.g. the glucocor-
ticoid receptor (GR) and peroxisome proliferator-activated
receptorgamma(PPARγ)[60].PPARγcoactivator1α(pro-
tein PGC-1α, gene PPARGC1A) is a well-established node
in the pathogenesis of diabetes and a master transcriptional
coactivator of mitochondrial genes [61]. Its expression is
decreased and related toimpaired ATP production as acon-
sequence of reduced oxidative phosphorylation in patients
with type 2 diabetes. It has also been reported that DNA
methylation of the PPARGC1A promoter is increased in
diabetic islets, demonstrating a plausible mechanism for
reduced PPARGC1A mRNA expression and insulin secre-
tioninpancreaticisletsofpatientswithtype2diabetes[62].
Consequently, super-optimal methyl donors from nutrition
may influence DNA methylation in the PPARGG1A pro-
moter region and therefore represent a potential epigenetic
cause for type 2 diabetes. Heterochromatin silencing and1094 Nephrol Dial Transplant (2009) 24: Editorial Reviews
histone H3-K9 methylation of heterochromatin transcrip-
tion and generation of heterochromatin-originated short
interfering RNA (siRNA) molecules have been shown in
fission yeasts [63]. This epigenetic regulation has specifi-
cally been timed during the S-phase of the cell cycle in a
temperature sensitive manner. In mammals, levels of DNA
methylationcorrelatewithage[64].Thissuggeststhatgene
expression may be repressed over time. It has been shown
that in the glomerulus ageing podocytes exhibit changed
geneexpressionpatterns[65].Inaddition,ithasbeenshown
that the developmental regulator Pax2 promotes assembly
of an H3K4 methyltransferease complex through nuclear
factor PTIP (Pax Transcription activation domain Interact-
ing Protein) [66]. The PTIP complex localizes to a Pax2
DNA-binding sequence and recruits the methyltransferease
complex.Intheembryo,together,Pax2andPax8areimpor-
tanttoregulatorsinducingnephricstructuresintheinterme-
diate mesoderm and urogenital epithelium [67]. Therefore,
Pax2 provides a kidney-specific locus for epigenetic mod-
ifications during development.
In addition, it has been shown that some genes that be-
come DNA hypermethylated and silenced in cancer cells
require intact DICER function for the maintenance of
their epigenetic status [68]. These results support the hy-
pothesis that RNA interference-mediated DNA methyla-
tion in cooperation with environmental responses modify
the genetic risk factors and the epigenetic inheritance of
heterochromatin.
MicroRNAs in insulin release regulation and
kidney actions
A subset of miRNAs has shown to be involved in metabolic
regulation of glucose homeostasis (Table 1). However, only
very few miRNA species have been fully characterized ex-
perimentally and most of their functions remain unknown.
Pancreatic islet-specific miR-375 inhibits insulin secretion
in mouse pancreatic β-cells by inhibiting the expression of
the protein myotrophin [69]. In addition, myotrophin, also
known as V-1, has been shown to interact with an actin-
capping protein inhibiting F-actin assembly, and to induce
exocytosis of insulin granules [69]. In another study, in-
creasing the level of miR-9 resulted in a severe defect in
glucose-stimulated insulin release by down-regulating the
transcription factor Onecut2 (OC2) [70]. OC2 represses
the activity and expression of Rab27a effector granuphilin,
which is a key component of the machinery controlling in-
sulin release [71]. Also miR-192 levels have been shown
to be increased in glomeruli isolated from streptozotocin-
injected diabetic mice as well as diabetic mice db/db when
compared to non-diabetic mice [24]. MiR-192 was shown
toregulateE-boxrepressorsthatareresponsibleforcontrol-
ling TGF-β induced extracellular matrix proteins collagen
1-α 1 and 2 (Col1a1 and 2) expression [24]. Col1a1 and
2 were shown to accumulate during diabetic nephropathy;
therefore,theseresultssuggestanpotentialroleofmiR-192
in kidney diseases.
Recently,acorrelationbetweenelevatedNotchsignalling
pathwaygeneexpressionanddiabeticnephropathyhasbeen
shown, in concert with Gremlin, the gene associated with
tubulointerstinal fibrosis in diabetic nephropathy [72], sug-
gesting the presence of miRNAs and CpG islands as a
potential regulatory strategy in this disease [73]. Interest-
ingly,distinctmiRNAsappeartomodifyNotchpathwaysin
Drosophila melanogaster with an effect in signalling cas-
cades determining cell specification and development [74].
Lai et al. showed that specific miRNAs regulated nega-
tive regulatory sequence motifs known as the GY box, the
Brd box and the K box in the 3  UTR of the Notch tar-
get genes [74]. These regulatory boxes have been shown
to serve as binding sites for miRNAs: GY-box is inhib-
ited by miR-7, Brd-box by miR-4 and miR-79, K-box by
miR-2 and miR-11; however, it remains to be determined
whetherthesemiRNAsregulateNotchsignallingindiabetic
nephropathy. MiR-143 has been experimentally shown to
regulate genes that are crucial for adipocyte differentia-
tion, (including GLUT4, HSL, fatty acid-binding protein
aP2 and PPAR-γ2) demonstrating a role for miRNAs in fat
metabolism and in endocrine function in humans [49]. In
addition, miR-15 and miR-16 have been proposed to con-
trol the Wnt/β-catenin signalling pathway during the em-
bryonal stage [75]. Wnt/β-catenin signalling regulates the
early events of nephrogenic induction during mouse kidney
development [76]; however, a regulatory role for miR-15 or
-16 has not yet been demonstrated during this process.
In the human kidney cortex, the renal glomerulus forms
the biological sieve that allows the passage of water and
smallmoleculeswhilemacromoleculese.g.albumincannot
normally pass beyond the filtration barrier [77]. Podocytes
surround the basement membrane of glomerular capillaries
from the outside and present specialized structures, foot
processes linked to each other forming the slit diaphragms
[78]. Therefore podocytes are considered to be critical for
maintaining the functional filtration barrier and preventing
albuminuria: alterations in slit diaphragm-associated genes
result in severe proteinuria [77].
While the association of podocytic miRNA and DNA
methylation profiles in health and disease is an important
topic to study, little is still known of the role of miRNAs
for this complex. General differences in miRNA expres-
sion as well as in the proteome profile have been shown
in the rat renal medulla and in the renal cortex region
using the microRNA microarray [40]. Very recent find-
ings of podocyte-specific deletion of Dicer demonstrated
a critical role for miRNA regulation in the progression of
glomerular and tubular damage, and therefore the develop-
mentofproteinuria[79,80].Dicerdeletioninpodocytesled
topodocyteapoptosisanddepletion;proteinuriawassignif-
icant 3 weeks after birth in mouse models. Also the rapid
progression of glomerular and tubular injury was promi-
nent at week 3, and culminated in death several weeks
later. Based on altered gene expression profile in podocyte-
specific Dicer knock-down glomeruli, especially the miR-
30 family has been highlighted as candidates participating
inpodocytehomestasisandpathogenesisofkidneydiseases
of podocyte origin. In another study with the podocyte-
specific Dicer knock-out mice, it was noticed that expres-
sionofslitdiaphragmproteinsnephrinandpodocinwasde-
creased[81–83].Inthisstudy,mmu-miR-23b,mmu-miR24
and mmu-miR26a were implicated as critical to maintain
the glomerular filtration barrier [81].Nephrol Dial Transplant (2009) 24: Editorial Reviews 1095
The rapid emergence and advances in high through-
put screening techniques facilitate focused research of
both genome-wide and cell-specific epigenetic and post-
transcriptional imprints in diabetes and kidney disease. Im-
proved understanding and identification of new epigenetic
andpost-transcriptionalregulatorymechanismsinvolvedin
theregulationofthekeymolecularcomplexesofpodocytes
will be of utmost importance in advancing diagnosis and
novel biomarker development, and in future therapeutics.
Acknowledgements. This study was supported by European Union FP6-
Lifescihealth-7 (DiaNa), The Sigrid Juselius Foundation of Finland and
Science Foundation Ireland.
Conflict of interest statement. None declared.
References
1. Dimitri P, Corradini N, Rossi F et al. The paradox of functional
heterochromatin. Bioessays 2005; 27: 29–41
2. Heitz E. Das heterochromatin der Moose. Jehrb Wiss Botanik 1928;
69: 762–818
3. Elgin SC, Grewal SI. Heterochromatin: silence is golden. Curr Biol
2003; 13: R895–R898
4. Bailis JM, Forsburg SL. S phase assembly of centromeric heterochro-
matin and cohesion. Cell Cycle 2004; 3: 416–418
5. Piacentini L, Fanti L, Berloco M et al. Heterochromatin protein 1
(HP1) is associated with induced gene expression in Drosophila eu-
chromatin. J Cell Biol 2003; 161: 707–714
6. Fuks F. DNA methylation and histone modifications: teaming up to
silence genes. Curr Opin Genet Dev 2005; 15: 490–495
7. Takai D, Jones PA. The CpG island searcher: a new WWW resource.
In Silico Biol 2003; 3: 235–240
8. Bird A. DNA methylation patterns and epigenetic memory. Genes
Dev 2002; 16: 6–21
9. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis:
epigenetics joins genetics. Trends Genet 2000; 16: 168–174
10. Eden A, Gaudet F, Waghmare A et al. Chromosomal instability and
tumors promoted by DNA hypomethylation. Science 2003; 300: 455
11. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG
dinucleotides in the human genome distinguishes two distinct classes
of promoters. Proc Natl Acad Sci USA 2006; 103: 1412–1417
12. Jenuwein T, Allis CD. Translating the histone code. Science 2001;
293: 1074–1080
13. Kaleem A, Hoessli DC, Ahmad, I et al. Immediate-early gene regu-
lation by interplay between different post-translational modifications
on human histone H3. J Cell Biochem 2008; 103: 835–851
14. Bernstein BE, Humphrey EL, Erlich RL et al. Methylation of histone
H3 Lys 4 in coding regions of active genes. Proc Natl Acad Sci USA
2002; 99: 8695–8700
15. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its
mediators. Trends Biochem Sci 2006; 31: 89–97
16. Kawasaki H, Taira K. Induction of DNA methylation and gene si-
lencing by short interfering RNAs in human cells. Nature 2004; 431:
211–217
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and func-
tion. Cell 2004; 116: 281–297
18. MoritaK,HanM.Multiplemechanismsareinvolvedinregulatingthe
expressionofthedevelopmentaltimingregulatorlin-28inCaenorhab-
ditis elegans. EMBO J 2006; 25: 5794–5804
19. Georgantas RW 3rd, Hildreth R, Morisot S et al.C D 3 4
+hematopoieticstem-progenitorcellmicroRNAexpressionandfunc-
tion: a circuit diagram of differentiation control. Proc Natl Acad Sci
USA 2007; 104: 2750–2755
20. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce
apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102:
13944–13949
21. Zhao Y, Srivastava D. A developmental view of microRNA function.
Trends Biochem Sci 2007; 32: 189–197
22. Miranda KC, Huynh T, Tay Y et al. A pattern-based method for the
identification of MicroRNA binding sites and their corresponding
heteroduplexes. Cell 2006; 126: 1203–1217
23. Perera RJ, Ray A. MicroRNAs in the search for understanding human
diseases. BioDrugs 2007; 21: 97–104
24. Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney
glomeruli and its function in TGF-beta-induced collagen expression
viainhibitionofE-boxrepressors.ProcNatlAcadSciUSA2007;104:
3432–3437
25. Cullen BR. Transcription and processing of human microRNA pre-
cursors. Mol Cell 2004; 16: 861–865
26. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-
dependent dsRNA-binding protein that mediates nuclear export of
pre-miRNAs. Rna 2004; 10: 185–191
27. Macrae IJ, Zhou K, Li F et al. Structural basis for double-stranded
RNA processing by Dicer. Science 2006; 311: 195–198
28. Tomari Y, Matranga C, Haley B et al. A protein sensor for siRNA
asymmetry. Science 2004; 306: 1377–1380
29. Stefani G, Slack FJ. Small non-coding RNAs in animal development.
Nat Rev Mol Cell Biol 2008; 9: 219–230
30. Nottrott S, Simard MJ, Richter JD. Human let-7a miRNA blocks
protein production on actively translating polyribosomes. Nat Struct
Mol Biol 2006; 13: 1108–1114
31. Humphreys DT, Westman BJ, Martin DI et al. MicroRNAs control
translation initiation by inhibiting eukaryotic initiation factor 4E/cap
and poly(A) tail function. Proc Natl Acad Sci USA 2005; 102: 16961–
16966
32. LiuJ,Valencia-SanchezMA,HannonGJetal.MicroRNA-dependent
localizationoftargetedmRNAstomammalianP-bodies.NatCellBiol
2005; 7: 719–723
33. Romao I, Roth J. Genetic and environmental interactions in obesity
and type 2 diabetes. J Am Diet Assoc 2008; 108: S24–S28
34. Hanson MA, Gluckman PD. Developmental origins of health and
disease: new insights. Basic Clin Pharmacol Toxicol 2008; 102: 90–
93
35. Gresham D, Dunham MJ, Botstein D. Comparing whole genomes
using DNA microarrays. Nat Rev Genet 2008; 9: 291–302
36. Shi H, Maier S, Nimmrich I et al. Oligonucleotide-based microarray
for DNA methylation analysis: principles and applications. J Cell
Biochem 2003; 88: 138–143
37. Ho SM, Tang WY. Techniques used in studies of epigenome dysregu-
lation due to aberrant DNA methylation: an emphasis on fetal-based
adult diseases. Reprod Toxicol 2007; 23: 267–282
38. Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in
human hepatoma cells: expression profiling the response to inhibition
ofDNAmethylationandhistonedeacetylation.BMCGenomics2006;
7: 181
39. Lewis BP, Shih IH, Jones-Rhoades MW et al. Prediction of mam-
malian microRNA targets. Cell 2003; 115: 787–798
40. Tian Z, Greene AS, Pietrusz JL et al. MicroRNA-target pairs in the
rat kidney identified by microRNA microarray, proteomic, and bioin-
formatic analysis. Genome Res 2008; 18: 404–411
41. Griffiths-Jones S, Saini HK, van Dongen S et al. miRBase: tools for
microRNA genomics. Nucleic Acids Res 2008; 36: D154–D158
42. Mardis ER. The impact of next-generation sequencing technology on
genetics. Trends Genet 2008; 24: 133–141
43. Kuhn DE, Martin MM, Feldman DS et al. Experimental validation of
miRNA targets. Methods 2008; 44: 47–54
44. Tang F, Hajkova P, O’Carroll D et al. MicroRNAs are tightly asso-
ciated with RNA-induced gene silencing complexes in vivo. Biochem
Biophys Res Commun 2008; 372: 24–29
45. Esau CC. Inhibition of microRNA with antisense oligonucleotides.
Methods 2008; 44: 55–60
46. Davis S, Lollo B, Freier S et al. Improved targeting of miRNA with
antisense oligonucleotides. Nucleic Acids Res 2006; 34: 2294–2304
47. Zamaratski E, Pradeepkumar PI, Chattopadhyaya J. A critical survey
of the structure-function of the antisense oligo/RNA heteroduplex as1096 Nephrol Dial Transplant (2009) 24: Editorial Reviews
substrate for RNase H. J Biochem Biophys Methods 2001; 48: 189–
208
48. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in
vivo with ‘antagomirs’. Nature 2005; 438: 685–689
49. Esau C, Kang X, Peralta E et al. MicroRNA-143 regulates adipocyte
differentiation. JB i o lC h e m2004; 279: 52361–52365
50. Junien C, Nathanielsz P. Report on the IASO Stock Conference
2006: early and lifelong environmental epigenomic programming of
metabolic syndrome, obesity and type II diabetes. Obes Rev 2007; 8:
487–502
51. Wallace TM, Matthews DR. Coefficient of failure: a methodology for
examining longitudinal beta-cell function in type 2 diabetes. Diabet
Med 2002; 19: 465–469
52. Robertson RP, Harmon J, Tran PO et al. Glucose toxicity in beta-
cells: type 2 diabetes, good radicals gone bad, and the glutathione
connection. Diabetes 2003; 52: 581–587
53. Cerda S, Weitzman SA. Influence of oxygen radical injury on DNA
methylation. Mutat Res 1997; 386: 141–152
54. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic
syndrome: new perspective against the epidemic. Diabetes 2005; 54:
1899–1906
55. Van Den Veyver IB. Genetic effects of methylation diets. Annu Rev
Nutr 2002; 22: 255–282
56. Morgan HD, Santos F, Green K et al. Epigenetic reprogramming in
mammals. Hum Mol Genet 2005; 14: R47–R58
57. Waterland RA, Garza C. Potential mechanisms of metabolic imprint-
ing that lead to chronic disease. Am J Clin Nutr 1999; 69: 179–197
58. Feil R. Environmental and nutritional effects on the epigenetic regu-
lation of genes. Mutat Res 2006; 600: 46–57
59. Devaskar SU, Thamotharan M. Metabolic programming in the patho-
genesis of insulin resistance. Rev Endocr Metab Disord 2007; 8: 105–
113
60. Simmons RA. Developmental origins of beta-cell failure in type 2
diabetes: the role of epigenetic mechanisms. Pediatr Res 2007; 61:
64R–67R
61. Scarpulla RC. Transcriptional paradigms in mammalian mitochon-
drial biogenesis and function. Physiol Rev 2008; 88: 611–638
62. Ling C, Del Guerra S, Lupi R et al. Epigenetic regulation of
PPARGC1A in human type 2 diabetic islets and effect on insulin
secretion. Diabetologia 2008; 51: 615–622
63. Kloc A, Zaratiegui M, Nora E et al. RNA interference guides histone
modification during the S phase of chromosomal replication. Curr
Biol 2008; 18: 490–495
64. Fraga MF, Esteller M. Epigenetics and aging: the targets and the
marks. Trends Genet 2007; 23: 413–418
65. Wiggins JE, Goyal M, Sanden SK et al. Podocyte hypertrophy, “adap-
tation,” and “decompensation” associated with glomerular enlarge-
ment and glomerulosclerosis in the aging rat: prevention by calorie
restriction. J Am Soc Nephrol 2005; 16: 2953–2966
66. PatelSR,KimD,LevitanIetal.TheBRCT-domaincontainingprotein
PTIPlinksPAX2toahistoneH3,lysine4methyltransferasecomplex.
Dev Cell 2007; 13: 580–592
67. Bouchard M, Souabni A, Mandler M et al. Nephric lineage specifica-
tion by Pax2 and Pax8. Genes Dev 2002; 16: 2958–2970
68. Ting AH, Suzuki H, Cope L et al. A requirement for DICER to
maintain fullpromoter CpGisland hypermethylation in human cancer
cells. Cancer Res 2008; 68: 2570–2575
69. Poy MN, Eliasson L, Krutzfeldt J et al. A pancreatic islet-specific
microRNA regulates insulin secretion. Nature 2004; 432: 226–230
70. Plaisance V, Abderrahmani A, Perret-Menoud V et al. MicroRNA-9
controlstheexpressionofGranuphilin/Slp4andthesecretoryresponse
of insulin-producing cells. JB i o lC h e m2006; 281: 26932–26942
71. Gomi H, Mizutani S, Kasai K et al. Granuphilin molecularly docks
insulin granules to the fusion machinery. J Cell Biol 2005; 171: 99–
109
72. Dolan V, Murphy M, Sadlier D et al. Expression of gremlin, a bone
morphogenetic protein antagonist, in human diabetic nephropathy.
Am J Kidney Dis 2005; 45: 1034–1039
73. WalshDW,RoxburghSA,McGettiganPetal.Co-regulationofGrem-
lin and Notch signalling in diabetic nephropathy. Biochim Biophys
Acta 2008; 1782: 10–21
74. Lai EC, Tam B, Rubin GM. Pervasive regulation of Drosophila Notch
target genes by GY-box-, Brd-box-, and K-box-class microRNAs.
Genes Dev 2005; 19: 1067–1080
75. Martello G, Zacchigna L, Inui M et al. MicroRNA control of Nodal
signalling. Nature 2007; 449: 183–188
76. Park JS, Valerius MT, McMahon AP. Wnt/beta-catenin signaling reg-
ulates nephron induction during mouse kidney development. Devel-
opment 2007; 134: 2533–2539
77. Patari-Sampo A, Ihalmo P, Holthofer H. Molecular basis of the
glomerular filtration: nephrin and the emerging protein complex at
the podocyte slit diaphragm. Ann Med 2006; 38: 483–492
78. Rodewald R, Karnovsky MJ. Porous substructure of the glomerular
slit diaphragm in the rat and mouse. J Cell Biol 1974; 60: 423–
433
79. ShiS,YuL,ChiuCetal.Podocyte-selectivedeletionofDicerinduces
proteinuriaandglomerulosclerosis.JAmSocNephrol2008;19:2159–
2169
80. Harvey SJ, Jarad G, Cunningham J et al. Podocyte-specific deletion
of Dicer alters cytoskeletal dynamics and causes glomerular disease.
J Am Soc Nephrol 2008; 19: 2150–2158
81. Ho J, Ng KH, Rosen S et al. Podocyte-specific loss of functional
microRNAs leads to rapid glomerular and tubular injury. J Am Soc
Nephrol 2008; 19: 2069–2075
82. Holzman LB, St John PL, Kovari IA et al. Nephrin localizes to the
slit pore of the glomerular epithelial cell. Kidney Int 1999; 56: 1481–
1491
83. Roselli S, Gribouval O, Boute N et al. Podocin localizes in the kidney
to the slit diaphragm area. Am J Pathol 2002; 160: 131–139
84. Chen L, Al-Awqati Q. Segmental expression of Notch and Hairy
genesinnephrogenesis.AmJPhysiolRenalPhysiol2005;288:F939–
F952
85. Huang TH, Laux DE, Hamlin BC et al. Identification of DNA methy-
lation markers for human breast carcinomas using the methylation-
sensitive restriction fingerprinting technique. Cancer Res 1997; 57:
1030–1034
86. HayashizakiY,HirotsuneS,OkazakiYetal.Restrictionlandmarkge-
nomic scanning method and its various applications. Electrophoresis
1993; 14: 251–258
87. Toyota M, Ho C, Ahuja N et al. Identification of differentially methy-
lated sequences in colorectal cancer by methylated CpG island ampli-
fication. Cancer Res 1999; 59: 2307–2312
88. Huang TH, Perry MR Laux DE. Methylation profiling of CpG is-
lands in human breast cancer cells. Hum Mol Genet 1999; 8: 459–
470
89. Frommer M, McDonald LE, Millar DS et al. A genomic sequencing
protocol that yields a positive display of 5-methylcytosine residues in
individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827–
1831
90. GitanRS,ShiH,ChenCMetal.Methylation-specificoligonucleotide
microarray: a new potential for high-throughput methylation analysis.
Genome Res 2002; 12: 158–164
91. CrossSH,CharltonJA,NanXetal.PurificationofCpGislandsusing
a methylated DNA binding column. Nat Genet 1994; 6: 236–244
92. Oberley MJ, Tsao J, Yau P et al. High-throughput screening of chro-
matin immunoprecipitates using CpG-island microarrays. Methods
Enzymol 2004; 376: 315–334
93. TostJ,SchatzP,SchusterMetal.Analysisandaccuratequantification
ofCpGmethylationbyMALDImassspectrometry.NucleicAcidsRes
2003; 31: e50.
Received for publication: 2.9.08
Accepted in revised form: 5.12.08